Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib Long-term Extension in PF-ILD (INBUILD® Extension)
CTR20190499Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Mar 2019; status: completed.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on CTR20190499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190499.